20-51432625-C-G
Position:
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_012340.5(NFATC2):āc.2164G>Cā(p.Val722Leu) variant causes a missense change. The variant allele was found at a frequency of 0.0000529 in 1,531,574 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.00026 ( 0 hom., cov: 32)
Exomes š: 0.000030 ( 0 hom. )
Consequence
NFATC2
NM_012340.5 missense
NM_012340.5 missense
Scores
3
4
12
Clinical Significance
Conservation
PhyloP100: 4.72
Genes affected
NFATC2 (HGNC:7776): (nuclear factor of activated T cells 2) This gene is a member of the nuclear factor of activated T cells (NFAT) family. The product of this gene is a DNA-binding protein with a REL-homology region (RHR) and an NFAT-homology region (NHR). This protein is present in the cytosol and only translocates to the nucleus upon T cell receptor (TCR) stimulation, where it becomes a member of the nuclear factors of activated T cells transcription complex. This complex plays a central role in inducing gene transcription during the immune response. Alternate transcriptional splice variants encoding different isoforms have been characterized. [provided by RefSeq, Apr 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (MetaRNN=0.06455976).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
NFATC2 | NM_012340.5 | c.2164G>C | p.Val722Leu | missense_variant | 9/11 | ENST00000371564.8 | NP_036472.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
NFATC2 | ENST00000371564.8 | c.2164G>C | p.Val722Leu | missense_variant | 9/11 | 1 | NM_012340.5 | ENSP00000360619 | A1 |
Frequencies
GnomAD3 genomes AF: 0.000256 AC: 39AN: 152134Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
39
AN:
152134
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000654 AC: 12AN: 183466Hom.: 0 AF XY: 0.0000511 AC XY: 5AN XY: 97828
GnomAD3 exomes
AF:
AC:
12
AN:
183466
Hom.:
AF XY:
AC XY:
5
AN XY:
97828
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000304 AC: 42AN: 1379322Hom.: 0 Cov.: 31 AF XY: 0.0000251 AC XY: 17AN XY: 677824
GnomAD4 exome
AF:
AC:
42
AN:
1379322
Hom.:
Cov.:
31
AF XY:
AC XY:
17
AN XY:
677824
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000256 AC: 39AN: 152252Hom.: 0 Cov.: 32 AF XY: 0.000296 AC XY: 22AN XY: 74442
GnomAD4 genome
AF:
AC:
39
AN:
152252
Hom.:
Cov.:
32
AF XY:
AC XY:
22
AN XY:
74442
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ESP6500AA
AF:
AC:
1
ESP6500EA
AF:
AC:
0
ExAC
AF:
AC:
7
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 07, 2023 | The c.2164G>C (p.V722L) alteration is located in exon 9 (coding exon 9) of the NFATC2 gene. This alteration results from a G to C substitution at nucleotide position 2164, causing the valine (V) at amino acid position 722 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Benign
.;T;.;.;.;.
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D;.;D;D
M_CAP
Benign
T
MetaRNN
Benign
T;T;T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
M;M;.;.;.;.
MutationTaster
Benign
D;D;D
PrimateAI
Uncertain
T
PROVEAN
Benign
N;N;.;.;N;.
REVEL
Benign
Sift
Benign
D;D;.;.;D;.
Sift4G
Benign
T;D;T;T;T;T
Polyphen
1.0
.;D;.;.;.;.
Vest4
MutPred
Loss of catalytic residue at V722 (P = 0.0243);Loss of catalytic residue at V722 (P = 0.0243);.;.;.;.;
MVP
MPC
0.73
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at